Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07150845 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
A Phase 2 study of Atoptic Dermatitis, sponsored by Evommune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT07150845 is a Phase 2 study of Atoptic Dermatitis that is actively recruiting participants, run by Evommune. The registered enrollment target is 120 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT07150845, a Phase 2 study of Atoptic Dermatitis, is actively recruiting participants, sponsored by Evommune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Conditions Studied
Interventions
- DRUG EVO756
- DRUG Placebo control
Study Locations (20)
Florida
- Skin Care Research, LLC - Boca Raton
- Driven Research, LLC - Coral Gables
- Skin Care Research - Hollywood Dermatology - Hollywood
- TrueBlue Clinical Research - Tampa
California
- Center for Dermatology Clinical Research - Fremont
- Metropolis Dermatology - Downtown Los Angeles - Los Angeles
- Skin and Beauty Center - Pasadena
New York
- Empire Dermatology - East Syracuse
- Equity Medical - New York
- Skin Search of Rochester, Inc. - Rochester
Michigan
- Great Lakes Research Group, Inc. - Bay City
- Revival Research Institute, LLC - Troy
Texas
- Stryde Research - Lewisville
- Progressive Clinical Research - San Antonio
Indiana
- DS Research - Clarksville
Kentucky
- Equity Medical - Bowling Green
Maryland
- Aesthetic and Dermatology Center - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07150845
The ClinicalTrials.gov registry entry for NCT07150845 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evommune, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atoptic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which EVO756 is the first listed.
NCT07150845 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT07150845 about?
NCT07150845 is a clinical study titled "Phase 2b Study of EVO756 in Adults With Atopic Dermatitis". This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
What is the current status of trial NCT07150845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-08-26. Estimated completion is 2026-07.
What conditions does trial NCT07150845 study?
This clinical trial studies the following conditions: Atoptic Dermatitis.
What interventions are being tested in trial NCT07150845?
The interventions under investigation include: EVO756 (DRUG), Placebo control (DRUG).
Who is sponsoring clinical trial NCT07150845?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07150845 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.